AGP Picks
View all

Amyotrophic Lateral Sclerosis (ALS) Market Size to Hit US$ 3,986.1 Million by 2033, Coherent Market Insights

News originally published by

GlobeNewswire

Rising ALS Prevalence, Advancements in Neurological Therapeutics, and Increasing Research Investments Support Global Market Growth. Copy Sub-Headline

Burlingame, CA, Nov. 16, 2026 (GLOBE NEWSWIRE) -- The Global Amyotrophic Lateral Sclerosis (ALS) Market is estimated to be valued at USD 1,818.0 million in 2026 and is projected to reach USD 3,986.1 million by 2033, registering a compound annual growth rate (CAGR) of 11.9% during 2026–2033. Market growth is primarily driven by the rising prevalence of amyotrophic lateral sclerosis, particularly among aging populations, increasing awareness of neurodegenerative disorders, and growing demand for effective treatment options. Additionally, advancements in gene-targeted therapies, increasing investments in neurological research and drug development, expanding clinical trial activities, and improving access to specialized neurological care are supporting the growth of the global amyotrophic lateral sclerosis market.

Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/9931

Global Amyotrophic Lateral Sclerosis (ALS) Market Key Takeaways

Based drug type, sodium phenylbutyrate and taurursodiol segment projected to account for the largest revenue share of 43.4% in 2026 as a result of

By route of administration, oral drugs are slated to hold 72.3% of the global amyotrophic lateral sclerosis (ALS) market share in 2026, owing to

Oral suspension is projected to account for a leading market share of 33.8% in 2026 because

North America is expected to dominate the global market with a 44.0% share in 2026, owing to

Asia Pacific, holding a share of 13.8% in 2026, is poised to emerge as the most lucrative market for Amyotrophic Lateral Sclerosis (ALS) drug manufacturers during the forecast period.

Growing Prevalence of ALS and Rising Disease Awareness Driving Market Growth

Coherent Market Insights' latest amyotrophic lateral sclerosis (ALS) market analysis outlines major factors spurring industry growth. These include increasing ALS prevalence, rising disease awareness, improved diagnosis rates, and growing investments in research and development of effective treatments.

Rising prevalence of amyotrophic lateral sclerosis (ALS) and growing awareness about the disease are providing a strong impetus for the growth of amyotrophic lateral sclerosis (ALS) market. ALS is a progressive neurological disorder that affects nerve cells responsible for controlling voluntary muscle movements. As the disease advances, patients experience muscle weakness and difficulties with walking, speaking, swallowing, and breathing. This creates a continued need for effective medicines and supportive treatment options.

According to the U.S. Centers for Disease Control and Prevention (CDC), the number of people living with ALS in the country is projected to increase from nearly 33,000 in 2022 to more than 36,000 by 2030. This, in turn, is expected to create a strong demand for amyotrophic lateral sclerosis drugs during the forecast period.

Growing awareness initiatives by healthcare organizations and patient advocacy groups are also encouraging early diagnosis and greater participation in clinical research. In addition, an aging population and improved recognition of neurological conditions are supporting demand for ALS treatments.

Limited Treatment Options and High Therapy Costs Hampering Market Growth

The global amyotrophic lateral sclerosis (ALS) market outlook remains positive due to rising disease prevalence, increasing awareness and diagnosis rates, growing investments in ALS research, and ongoing development of novel treatment options. However, availability of limited treatment options and high therapy costs might slow amyotrophic lateral sclerosis (ALS) market growth.

Available medicines can help manage symptoms or slow disease progression in some patients, but there is currently no cure for ALS. The complex nature of the disease also makes it difficult to develop treatments that can deliver consistent clinical benefits. Moreover, the high cost of specialized medicines and long-term care can limit access to treatment, particularly in countries with limited healthcare coverage.

Advances in Targeted ALS Therapies Creating Lucrative Growth Opportunities

Increasing research into genetic and molecular causes of ALS is creating new opportunities for market players. Researchers are developing therapies that target specific genetic mutations and biological pathways associated with the disease. Such approaches could help improve treatment options for patients with genetically defined forms of ALS.

For instance, tofersen is an antisense oligonucleotide therapy developed for adults with ALS associated with a mutation in the SOD1 gene. Its approval has highlighted the potential of genetic testing and targeted treatment approaches in ALS care. Continued research into antisense oligonucleotides, RNA-based therapies as well as gene-targeted treatments is expected to create new opportunities for pharmaceutical and biotechnology companies.

Immediate Delivery Available | Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/9931

Emerging Amyotrophic Lateral Sclerosis (ALS) Market Trends

Growing use of biomarkers in ALS diagnosis and treatment monitoring is a key market –shaping trend. Biomarkers are gaining importance in ALS research as they can help identify disease-related changes and monitor treatment response. Neurofilament light chain (NfL), for example, is being studied as a marker of nerve cell damage and disease progression. Its use in clinical trials can help researchers assess treatment effects and improve patient selection. Advances in blood-based testing are also creating possibilities for earlier disease detection.

Increasing focus on genetically targeted therapies is supporting expansion of the ALS market. Pharmaceutical companies are increasingly focusing on treatments designed to target specific genetic mutations associated with ALS. Research into mutations involving SOD1, FUS, and C9orf72 is supporting development of antisense oligonucleotide as well as other gene-targeted therapies. These approaches may help address underlying disease mechanisms rather than focusing only on symptom management.

Growing adoption of platform-based clinical trials is expected to boost market growth during the forecast period. Platform-based clinical trials are gaining attention in ALS research because they allow multiple investigational treatments to be evaluated through a shared trial structure. This approach can help researchers compare treatment outcomes, improve trial efficiency as well as reduce the need to establish separate infrastructure for every therapy. Greater use of these trials could support faster evaluation of promising ALS drug candidates.

Rising use of digital tools for ALS monitoring is also fostering market growth. Digital health technologies are creating new ways to monitor changes in ALS patients outside traditional clinical settings. Wearable devices, remote monitoring platforms as well as digital assessment tools can help track movement, speech, and other functional changes over time. These technologies may support more frequent patient assessments and provide useful data for clinical research and treatment monitoring.

Analyst’s View

“The global amyotrophic lateral sclerosis market is expected to witness steady growth as pharmaceutical companies and research institutions continue to focus on developing more effective treatment options. Growing interest in genetically targeted therapies, biomarker-based research, and improved clinical trial methods is creating new opportunities for market participants. Companies investing in innovative drug development and strategic research collaborations are likely to strengthen their position in this evolving market,” said a senior analyst at CMI.

Current Events and Their Impact on the Amyotrophic Lateral Sclerosis (ALS) Market

Event Description and Impact
EMA Proposes Revision of ALS Clinical Trial Guidelines (March 2026)
  • Description: The European Medicines Agency (EMA) proposed revisions to its guidelines for clinical investigations of medicines used to treat ALS. The proposed changes reflect developments in drug research and clinical trial methods.
  • Impact: Updated clinical trial guidelines could help pharmaceutical companies design more relevant studies and support the development of new ALS treatments.
Coya Therapeutics Receives FDA Fast Track Designation for COYA 302 (May 2026)
  • Description: Coya Therapeutics announced that the U.S. FDA granted Fast Track Designation to its investigational therapy COYA 302 for ALS. The therapy is being evaluated in a Phase 2 clinical trial and aims to reduce inflammation by improving immune-system function.
  • Impact: The designation could facilitate more frequent discussions with the FDA and support the clinical development of COYA 302, potentially expanding future treatment options for ALS patients.

Competitor Insights

Key companies in the amyotrophic lateral sclerosis (ALS) market report include:

  • Biogen Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Sanofi
  • Otsuka Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • Ionis Pharmaceuticals, Inc.
  • AB Science
  • BrainStorm Cell Therapeutics Inc.
  • Clene Inc.
  • Sun Pharmaceutical Industries Limited

Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/9931

Key Developments

In May 2026, Coya Therapeutics announced that the U.S. FDA had granted Fast Track Designation to COYA 302, an investigational biologic combination therapy for ALS. The company is evaluating the treatment in a Phase 2 clinical trial, reflecting continued efforts to develop therapies targeting inflammation and immune-system activity.

In September 2025, an NIH-supported research study reported the development of a protein-based blood test model that detected ALS with more than 98% accuracy in the study. The findings could support further development of blood-based diagnostic methods and improve disease research.

Market Segmentation

  • Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
    • Sodium Phenylbutyrate and Taurursodiol
    • Edaravone
    • Nuedexta
    • Tofersen
    • Riluzole
    • Muscle Relaxants
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Others
  • Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
    • Oral
    • Parenteral
    • Others
  • Dosage Form Insights (Revenue, USD Mn, 2021 - 2033)
    • Oral Suspension
    • Injectable
    • Tablets
    • Others
  • Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Regional Insights (Revenue, USD Mn, 2021 - 2033)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa

Related Reports:
Anti-Inflammatory Drugs Market Trends, Drivers, and Growth Opportunities for 2026-2033
Amyotrophic Lateral Sclerosis Treatment Market Outlook and Forecast for 2026-2033
Multiple Sclerosis Therapeutics Market Size, Share, Trends & Opportunities for 2026-2033


Mr. Shah
Coherent Market Insights
533 Airport Boulevard,
Suite 400, Burlingame,
CA 94010, United States
US: + 12524771362
UK: +442039578553
AUS: +61-8-7924-7805
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Myanmar Business Daily

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.